The company's net profit for the same quarter last year stood at Rs 6.27 crore.
The consolidated total revenues during the quarter under review grew by 25.23% to Rs 252.33 crore from Rs 201.74 crore in the corresponding previous quarter.
Also Read
The company maintained that the growth was driven by strong performance across all the three verticals, namely, finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients.
It said the formulation expansion at the Gagilapur facility commenced operations during the quarter and the company expects to scale up production throughout the year as it receives customer approvals.
However, the company has apparently insulated the first quarter's balance sheet from the adverse impact of exchange rate fluctuation on loans.
During the quarter a loss of Rs 14.78 crore(loss of Rs 8.30 crore for the quarter ended June, 2013) was transferred to fixed assets as the company has opted to capitalise foreign currency gains and losses on loans utilised for purchase of fixed assets, the company said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
